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The mechanisms leading to the retraction of the granulation
tissue during wound healing have not been fully elucidated to
date [reviewed in I]. Our laboratory several years ago described
that fibroblasts present in granulation tissue exhibit several
ultrastructural features of smooth muscle cells, including the
presence of microfilament bundles with dense bodies scattered
within [21. These cells, called myofibroblasts, have been pro-
posed to play a retractile role in several conditions such as
granulation tissue contraction, parenchymal organ retraction,
fibromatosis and stromal reaction to epithelial tumors [reviewed
in 3]. The coincidence of the presence of myofibroblasts with
retractile phenomena has supported this hypothesis. However,
direct proof of the presence and activity of contractile elements
in myofibroblasts has been possible only after suitable tech-
niques have been developed to localize and quantify cytoskel-
etal and contractile proteins within the affected organs. For this
purpose, the advances in the understanding of cytoskeletal and
contractile element morphology and biochemistry in different
cells have been of great value [reviewed in 4]. Presently, we
know that the cytoskeleton of mesenchymal cells is composed
of intermediate filaments which consist of a single protein
named vimentin. In muscle cells, however, most intermediate
filaments have been shown to contain another related, but not
identical, protein which is called desmin. However, vascular
smooth muscle cells always express vimentin, and only a
proportion of them contains in addition desmin. Moreover,
desmin has been increasingly found in a number of nonmuscle
mesenchymal cells such as endothelial cells [5,6], podocytes [7]
and stromal cells from various locations [7—10]. Another marker
of tissue origin is the presence of a specific actin isoform, since
the six actin isoform expressing mammals show a tissue specific
distribution [41. In particular, a-smooth muscle actin is present
in all smooth muscle cells. Finally, isoforms of myosin heavy
and light chains can also be typical of smooth muscle (particu-
larly under normal conditions) and hence assist in identifying
cells which are involved in different pathological changes [11].
Using different markers, we have defined four cytoskeletal
phenotypes among myofibroblasts: I) phenotype V represented
by myofibroblasts positive for vimentin only; 2) phenotype VA
represented by myofibroblasts positive for vimentin and
a-smooth muscle actin; 3) phenotype VAD represented by
myofibroblasts positive for vimentin, a-smooth muscle actin
and desmin; and 4) phenotype VD represented by myofibro-
blasts positive for vimentin and desmin. When normally healing
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granulation tissue is studied with these criteria, during granu-
lation tissue contraction a high proportion of myofibroblasts
have been found to develop the expression of a-smooth muscle
actin, but not of desmin and smooth muscle myosin [121, and
hence acquire, at least in part, smooth muscle features. When
contraction stops and the wound is fully epithelialized, myofi-
broblasts containing a-smooth muscle actin disappear, proba-
bly by apoptosis, and the scar classically becomes less cellular
and composed of typical fibroblasts with well developed rough
endoplasmic reticulum and no more microfilaments, nor
a-smooth muscle actin. In more permanent retractile conditions
and in particular in kidney, lung or liver fibrosis, myofibroblasts
expressing a-smooth muscle actin are constantly present, and
in addition, a proportion of them also express desmin [13].
However, at present, no myofibroblast expressing smooth
muscle myosin has been described [11, 14]. On the basis of
these results, we propose that during the development of
fibrocontractive diseases, fibroblasts acquire contractile fea-
tures and produce the centripetal force leading to retraction.
For this purpose, myofibroblasts have the capacity of develop-
ing connections to the surrounding extracellular matrix and
hence to act on the whole tissue [3]. Traction rather than
contraction forces have been shown to be responsible for the
retractile activity of cultured fibroblasts on their substratum
[15]. In analogy with these observations, we suggest that the
retractile activity of myofibroblasts during fibrotic changes is
more dependent in isometric contraction than on isotonic
contraction.
What remains to be explored are the mechanisms leading to
the development of cytoskeletal features similar to those of
smooth muscle cells in fibroblasts, including the factors which
can regulate, in vivo and in vitro, the appearance of a-smooth
muscle actin and desmin. The more likely candidates for these
actions are cytokines, which can be locally liberated by vascu-
lar cells, inflammatory cells and fibroblastic cells themselves, as
well as extracellular matrix components which have been
shown to influence the shape, the replication and the develop-
ment of cytoskeletal features in fibroblastic and smooth muscle
cells [reviewed in 3]. Working along these lines, we have
observed that y-interferon, a cytokine mainly produced by
T-helper lymphocytes is capable of inhibiting the expression of
a-smooth muscle actin in both smooth muscle [161 and fibro-
blasts [17]. When y-interferon is applied to Dupuytren's nod-
ules, it produces an improvement of the retractile conditions
and in hypertrophic scars, in addition to the reduction of the
size of the lesion, it elicits the disappearance of a-smooth
muscle actin in myofibroblasts (unpublished observation).
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Although further studies are needed to confirm these prelim-
inary results, we feel that work in these directions can help not
only the understanding of the pathogenesis of fibrocontractive
diseases, but also may reveal future directions for treatment. In
this respect, we have observed in an experimental rat model
that the application of GM-CSF to the subcutaneous tissue
induces not only the proliferation of fibroblasts and the forma-
tion of ultrastructurally typical myofibroblasts, but also the
expression of a-smooth muscle actin in a significant proportion
of these cells [18]. GM-CSF is mainly known for its hematopoi-
etic effect [19], but some extra-hematopoietic activity has been
attributed to this factor. Thus, GM-CSF stimulates migration of
human endothelial cells [19] and proliferation of different non-
hematopoietic cells of mesenchymal origin in vitro, such as
endothelial cells [20], bone marrow fibroblast precursors, and
several transformed cell lines [21]. Moreover, in transgenic
mice expressing GM-CSF, fibrotic nodules developed in areas
where macrophages accumulate [22]. These lesions have been
interpreted as following chronic macrophage activation induced
by GM-CSF. However, another study did not detect any side
effects in response to long-term GM-CSF treatment in mice
[23]. Clearly, these experiments need further confirmation, but
they indicate that progress in the understanding of cytokine
effects on fibroblastic cells may furnish explanation for the
mechanisms leading to the development of a contractile pheno-
type in fibroblasts. It is well known that heparin and heparan
sulfates inhibit smooth muscle cell replication and increase the
expression of a-smooth muscle actin in these cells [24]. We
have also observed that heparin and heparan sulfates exert
similar action on fibroblastic cells and hence they could also
participate in the regulation of fibroblastic phenotype during
wound healing and different retractile diseases (unpublished
observation).
In conclusion, the early observation that fibroblasts modify
their phenotype during wound healing and fibrocontractive
diseases has been implemented by several biochemical and
functional findings which support the idea that myofibroblasts
are a key cell for the understanding of retractile phenomena.
Further studies on the factors regulating the phenotype of
myofibroblasts will be useful for understanding their behavior in
vivo, and possibly modifying this behavior during the different
clinical settings.
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